Actualités

L’évolocumab réduit de 44 % le taux de LDL-C chez les enfants atteints d’hypercholestérolémie familiale

Evolocumab (Repatha) significantly improved low-density lipoprotein cholesterol (LDL-C) levels in pediatric patients with familial hypercholesterolemia, according to a new study.

The phase 3 findings, presented during a late-breaking session at the European Society of Cardiology (ESC) 2020 Congress this weekend, give clinicians incentive to further understand the benefit of the PCSK9 inhibitor drug class among children suffering from the most common monogenic disorder in the world.

Lire l'article sur HCP Live